U10. Drug Formulation
-
- Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
- Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
- Entities: Universidad del País Vasco (UPV/EHU)
- Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
- Phone: +34 653593042
- Fax: +34 945 013040
- Web: NANOBIOCEL UPV/EHU
Order request
Description
Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.
This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.
The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.
The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.
One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency
Services
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
U10. Services & Rates
Other projects
| Ref |
Title |
Funding Organism |
Unit Role |
| RTC-2016-4770-1 |
DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE |
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. |
Participant |
| RTC-2016-5451-1 |
DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION |
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD. |
Participant |
| RTC-2015-3303-1 |
Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS |
MINISTERIO DE ECONOMIA Y COMPETITIVIDAD |
|
Publications
2016
- Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
- Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
- Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
- Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
- Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
- Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.
News U10
23 Nov
Researchers of NANBIOSIS U10 “Drug Formulation” – NanoBiocel research group from CIBER-BBN and UPV/EHU receives 3 awards in the category of Best International Articles at the annual Bioaraba Research and Innovation Conference. On 4 November, the Bioaraba Health Research Institute held its XXIII Research and Innovation Conference in Vitoria. This important annual forum held in [...]
27 Oct
On October 18 and 19, was held the second course on Social Communication of Science, orgnized by NANBIOSIS U10 Drug Formulation Unit -(NanoBioCell Group of CIBER-BBN and UPV-EHU, this year entitled “Tools for the social communication of science“. The course aimed to provide doctoral students with communication with tools to be employed in their work [...]
09 Oct
The NanoBioCel group of the CIBER BBN, which also runs NANBIOSIS U10 Drug Formulation unit , organized the Workshop #6 of the Moore4medical European project at the Alava Technology Park on October 4, 5 and 6 The Central Building of the Álava Technology Park hosted the ‘Workshop #6’ of the European project which. 80 people [...]
29 Apr
Cystic fibrosis is an inherited genetic disease that mainly affects the lungs and the digestive system On April 6, the first meeting was held, on the one hand, with people with Cystic Fibrosis and the Euskadi Cystic Fibrosis Association (Arnasa) and, on the other, with the NanoBioCel research group of the CIBER-BBN and the University [...]
05 Apr
Cystic Fibrosis is a genetic disorder that affects mostly the lungs, but also the pancreas, liver, kidneys, and intestine. It is a genetic, degenerative and chronic disease, with a population incidence is 1 in 5,000, so it is considered among the so called “Rare Diseases” The most common symptoms are continuous colds, repeated infections, decreased lung capacity, impossibility of fat absorption and [...]
22 Mar
In the picture: microencapsulated cardiospheres 10X Captured Brightfield with DM_RGB_Brightfield with DM The European project POSITION-II has been selected for publication in the ‘Results in Brief’ section of the Community Research and Development Information Service (CORDIS) website. CORDIS is the European Commission’s primary source of results from the projects funded by the EU’s framework programmes [...]
15 Feb
The leader of the NanoBioCell Group form CIBER-BBN and UPV/EHU, Jose Luis Pedraz, and the reaearches Laura Saenz del Burgo and Markel Lafuente have received the 2021 Award from the Academy of Pharmacy of Castilla y León, on February 4, at the city of Salamanca, for the work entitled: “Design and Characterization of a biotin [...]
13 Jan
Edorta Santos Vizcaíno has been awarded as Best Emerging Researcher in the biomedical area by the Bioaraba Health Research Institute in the XXII edition of the Research and Innovation Conference. This award aims to recognize the work of researchers under the age of 40 who carry out their research activity in any public center of [...]
26 Nov
The Unit 10 of Drug Formulation of the ICTS NANBIOSIS coordinated by the CIBER-BBN NanoBioCel group directed by Jose Luis Pedraz, which belongs to the University of the Basque Country, has been present at the signing of the agreement that gives support by the Provincial Council of Alava within the framework of the Advance Pharma [...]
14 Oct
Cáceres, October 14th, 2021 POSITION II has received funding within the Electronic Components and Systems for European Leadership Joint Undertaking (ECSEL JU) in collaboration with the European Union’s H2020 Framework Programme (H2020/2014-2020) and National Authorities, under grant agreement Ecsel-783132-Position-II-2017-IA. It promotes innovation in smart medical instruments and focuses in the next generation of smart catheters [...]
